Agilent (A) Q3 2026 Earnings Report

The call conveyed strong operational and financial momentum: solid top-line beats, meaningful margin expansion (noting some benefit from one-time tariff refunds), raised full-year guidance, robust cash generation, continued product and China momentum, and visible benefits from the Ignite transformation. Lowlights were largely timing, one-time refund effects, regional softness in pockets (Europe, parts of C&E) and near-term variability related to CDMO ramp timing and macro/cost pressures. On balance the positives substantially outweighed the negatives.

Agilent raised its FY26 outlook to reported revenue of $7.49–$7.51 billion (core/organic constant‑currency growth 5.8%–6.0%; currency a ~1.6% tailwind) and increased full‑year EPS to $6.18–$6.21 including roughly $0.06 (≈$20M) of Q3 tariff‑refund benefit (ex‑refund EPS $6.12–$6.15, ~10% y/y growth at the midpoint; including refunds ≈11% growth). Management now expects operating‑margin expansion ex‑refund of >100 basis points at the midpoint (>130 bps including Q3 refunds), a tax rate of 14.5%, other income of $31M, 283M diluted shares outstanding, operating cash flow of $1.6–$1.7B and ~ $450M of capex. Q4 guidance is revenue $1.98–$2.00B (core growth ~5.2%–6.2%; ~10 bps currency headwind), EPS $1.71–$1.74 (8%–9% growth), includes ~ $23M from Biocare and excludes any future tariff‑refund benefit. Segment and regional assumptions were raised (CAM to high single‑digits; AMG and LDG to mid‑ to high‑single‑digits; ACG mid‑single‑digit; China mid‑single‑digits; Asia ex‑China double‑digits; Europe low single‑digits; Americas mid‑ to high‑single‑digits), and the revised guide implies a two‑year stacked core acceleration to ~11% versus flat in 2025.